NCT00030394View on ClinicalTrials.gov

Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia

PHASE2CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

September 30, 2002

Primary Completion Date

October 31, 2007

Conditions
Childhood Chronic Myelogenous LeukemiaChronic Myelogenous Leukemia, BCR-ABL1 PositiveChronic Phase Chronic Myelogenous Leukemia
Interventions
DRUG

imatinib mesylate

Given orally

OTHER

laboratory biomarker analysis

Correlative studies

OTHER

pharmacological study

Correlative studies

Trial Locations (1)

91006-3776

Children's Oncology Group, Arcadia

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00030394 - Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia | Biotech Hunter | Biotech Hunter